Trials / Completed
CompletedNCT02712008
Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI) in improving best corrected visual acuity (BCVA) in participants with diabetic macular edema (DME).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN910-3 | Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept) |
| DRUG | Intravitreal Aflibercept Injection (IAI) |
Timeline
- Start date
- 2016-03-02
- Primary completion
- 2017-07-10
- Completion
- 2017-07-10
- First posted
- 2016-03-17
- Last updated
- 2018-10-03
- Results posted
- 2018-10-03
Locations
51 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02712008. Inclusion in this directory is not an endorsement.